UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. Besides those cuts, the company removed eczema and heart failure prospects from its pipeline.
Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. Besides those cuts, the company removed eczema and heart failure prospects from its pipeline.
